InflaRx N.V 6-K, filed Aug 7, 2025

InflaRx N.V. (IFRX)

6-K 2025-08-07 For: 2025-06-30

View Original

Added on April 09, 2026

About this 6-K

InflaRx N.V filed this 6-K on August 7, 2025.

Search and read filings like this one from Claude or ChatGPT with the SEC filings MCP server →

Exhibit No.		Description
99.1		InflaRx N.V. Unaudited Condensed Consolidated Financial Statements as of and for the Six Months Ended June 30, 2025
99.2		InflaRx N.V. Management’s Discussion and Analysis of Financial Condition and Results of Operations
99.3		InflaRx N.V. Press Release dated August 7, 2025
101.INS		Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document
101.SCH		Inline XBRL Taxonomy Extension Schema Document
101.CAL		Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF		Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB		Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE		Inline XBRL Taxonomy Extension Presentation Linkbase Document

	INFLARX N.V.
Date: August 7, 2025	By:	/s/ Niels Riedemann
	Name:	Niels Riedemann
	Title:	Chief Executive Officer

Unaudited condensed consolidated statements of operations and comprehensive loss for the	F-3
Unaudited condensed consolidated statements of financial position	F-4
Unaudited condensed consolidated statements of changes in shareholders’ equity for the	F-5
Unaudited condensed consolidated statements of cash flows for the six months ended June 30, 2025 and 2024	F-6
Notes to the unaudited condensed consolidated financial statements	F-7
1. Summary of significant accounting policies and other disclosures	F-7
a) Reporting entity and the Group’s structure	F-7
b) Basis of preparation	F-7
2. Revenues	F-8
3. Cost of sales	F-8
4. Sales and marketing expenses	F-8
5. Research and development expenses	F-8
6. General and administrative expenses	F-9
7. Other income	F-9
8. Net financial result	F-9
9. Inventory	F-10
10. Other assets	F-10
11. Tax receivables	F-11
12. Financial assets and financial liabilities	F-11
13. Other liabilities	F-12
14. Cash and cash equivalents	F-12
15. Equity	F-12
16. Share-based payments	F-13
a) Equity settled share-based payment arrangements	F-13
b) Share-based payment expense recognized	F-14
c) Share options exercised	F-14
17. Protective foundation	F-14

			For the three months ended June 30,						For the six months ended June 30,
	Note		2025 (unaudited)			2024 (unaudited)			2025 (unaudited)			2024 (unaudited)
			(in €, except for share data)

Revenues		2		39,432			6,357			39,432			42,394
Cost of sales		3		(2,399,583	)		(348,153	)		(2,408,874	)		(568,674	)
Gross profit (loss)				(2,360,151	)		(341,796	)		(2,369,442	)		(526,280	)
Sales and marketing expenses		4		(1,013,347	)		(1,828,628	)		(2,471,326	)		(3,288,167	)
Research and development expenses		5		(7,202,942	)		(10,016,870	)		(14,219,279	)		(17,318,680	)
General and administrative expenses		6		(3,279,485	)		(3,226,098	)		(8,342,090	)		(6,805,249	)
Other income		7		937,938			16,730			1,479,035			53,023
Other expenses				—			—			(26	)		—
Operating result				(12,917,988	)		(15,396,663	)		(25,923,127	)		(27,885,353	)
Finance income		8		522,221			848,243			1,015,985			1,754,148
Finance expenses		8		(3,355	)		(8,732	)		(7,441	)		(10,844	)
Foreign exchange result		8		(2,869,983	)		711,411			(4,778,812	)		2,535,787
Other financial result		8		852,834			—			6,963,097			103,285
Income taxes				—			—			—			—
Income (loss) for the period				(14,416,271	)		(13,845,741	)		(22,730,298	)		(23,502,977	)
Other comprehensive income (loss) that may be reclassified to profit or loss in subsequent periods:
Exchange differences on translation of foreign currency				(113,604	)		28,374			(264,271	)		2,836
Total comprehensive income (loss)				(14,529,876	)		(13,817,367	)		(22,994,569	)		(23,500,141	)

Share information
Weighted average number of shares outstanding				67,747,130			58,883,272			65,542,269			58,883,272
Income (loss) per share (basic/diluted)				(0.21	)		(0.24	)		(0.35	)		(0.40	)

	Note		June 30, 2025 (unaudited)			December 31, 2024
			(in €)
ASSETS
Non-current assets
Property and equipment				247,027			256,280
Right-of-use assets				559,286			758,368
Intangible assets				50,106			50,781
Other assets		10		177,716			204,233
Financial assets		12		6,235,346			3,092,290
Total non-current assets				7,269,480			4,361,952
Current assets
Inventories		9		5,038,415			6,897,666
Current other assets		10		5,519,954			5,103,402
Other assets from government grants and research allowance		10		5,863,947			5,081,772
Tax receivables		11		1,753,638			1,735,335
Financial assets		12		34,993,289			34,462,352
Cash and cash equivalents		14		13,003,450			18,375,979
Total current assets				66,172,692			71,656,505
TOTAL ASSETS				73,442,172			76,018,457

EQUITY AND LIABILITIES
Equity
Issued capital		15		8,129,656			7,122,205
Share premium				348,956,615			334,929,685
Other capital reserves				47,704,375			44,115,861
Accumulated deficit				(354,922,519	)		(332,192,221	)
Other components of equity				7,176,239			7,440,510
Total equity				57,044,365			61,416,039
Non-current liabilities
Lease liabilities				203,878			399,066
Other liabilities		13		36,877			36,877
Total non-current liabilities				240,755			435,943
Current liabilities
Trade and other payables		12		9,735,656			11,394,232
Lease liabilities				395,234			406,020
Employee benefits				1,114,635			2,064,678
Liabilities to warrant holders				4,549,915			—
Other liabilities		13		361,613			301,544
Total current liabilities				16,157,053			14,166,475
Total Liabilities				16,397,808			14,602,417
TOTAL EQUITY AND LIABILITIES				73,442,172			76,018,457

(in €, except for share data)	Note		Shares outstanding		Issued capital		Share premium			Other capital reserves		Accumulated deficit			Other compo- nents of equity			Total equity

Balance as of January 1, 2025				59,351,710		7,122,205		334,929,685			44,115,861		(332,192,221	)		7,440,510			61,416,039
Loss for the period				—		—		—			—		(22,730,298	)		—			(22,730,298	)
Exchange differences on translation of foreign currency				—		—		—			—		—			(264,271	)		(264,271	)
Total comprehensive loss				—		—		—			—		(22,730,298	)		(264,271	)		(22,994,569	)
Issuance of ordinary shares				8,395,420		1,007,450		15,136,235			—		—			—			16,143,686
Transaction costs for ordinary shares				—		—		(1,109,305	)		—		—			—			(1,109,305	)
Equity-settled share-based payments		16		—		—		—			3,588,514		—			—			3,588,514
Balance as of June 30, 2025				67,747,130		8,129,656		348,956,615			47,704,375		(354,922,519	)		7,176,239			57,044,365

Balance as of January 1, 2024				58,883,272		7,065,993		334,211,338			40,050,053		(286,127,819	)		7,382,166			102,581,730
Loss for the period				—		—		—			—		(23,502,977	)		—			(23,502,977	)
Exchange differences on translation of foreign currency				—		—		—			—		0			2,836			2,836
Total comprehensive loss				—		—		—			—		(23,502,977	)		2,836			(23,500,141	)
Equity-settled share-based payments		16		—		—		—			3,073,814		—			—			3,073,814
Balance as of June 30, 2024				58,883,272		7,065,993		334,211,338			43,123,867		(309,630,796	)		7,385,002			82,155,403

	As of June 30, 2025 (unaudited)		As of December 31, 2024
	(in €)

Raw material and supplies		82,090		82,087
Unfinished goods		4,902,547		6,758,952
Finished goods		53,778		56,627
Total		5,038,415		6,897,666

Number of share options	2025		2024
Outstanding as of January 1,		148,433		148,433
Exercised during the six months ended June 30		—		—
Outstanding as of June 30,		148,433		148,433
thereof vested / exercisable		148,433		148,433

Share options granted 2025	Number		Fair value per option		FX rate as of grant date		Fair value per option		Share price at grant date / Exercise price		Expected volatility		Expected life (midpoint based)		Risk-free rate (interpolated, U.S. sovereign strips curve)

January 03		2,452,000	$	1.86		0.971	€	1.81	$	2.41		0.97		5.5		0.04435
		2,452,000

	three months ended June 30,
	2025			2024			Change
	(in €)
Revenues		39,432			6,357			33,075
Cost of sales		(2,399,583	)		(348,153	)		(2,051,429	)
Gross profit		(2,360,151	)		(341,796	)		(2,018,354	)
Operating expenses
Sales and marketing expenses		(1,013,347	)		(1,828,628	)		815,280
Research and development expenses		(7,202,942	)		(10,016,870	)		2,813,928
General and administrative expenses		(3,279,485	)		(3,226,098	)		(53,387	)
Total operating expenses		(11,495,775	)		(15,071,596	)		3,575,821
Other income		937,938			16,730			921,208
Other expenses		—			—			—
Operating result		(12,917,988	)		(15,396,663	)		2,478,675
Finance income		522,221			848,243			(326,022	)
Finance expenses		(3,355	)		(8,732	)		5,377
Foreign exchange result		(2,869,983	)		711,411			(3,581,394	)
Other financial result		852,834			—			852,834
Income taxes		—			—			—
Income (loss) for the period		(14,416,271	)		(13,845,741	)		(570,531	)
Exchange differences on translation of foreign currency		(113,604	)		28,374			(141,978	)
Total comprehensive income (loss)		(14,529,876	)		(13,817,367	)		(712,509	)

	six months ended June 30,
	2025			2024			Change
	(in €)
Revenues		39,432			42,394			(2,962	)
Cost of sales		(2,408,874	)		(568,674	)		(1,840,200	)
Gross profit		(2,369,442	)		(526,280	)		(1,843,162	)
Operating expenses
Sales and marketing expenses		(2,471,326	)		(3,288,167	)		816,841
Research and development expenses		(14,219,279	)		(17,318,680	)		3,099,401
General and administrative expenses		(8,342,090	)		(6,805,249	)		(1,536,841	)
Total operating expenses		(25,032,694	)		(27,412,095	)		2,379,401
Other income		1,479,035			53,023			1,426,012
Other expenses		(26	)		—			(26	)
Operating result		(25,923,127	)		(27,885,353	)		1,962,226
Finance income		1,015,985			1,754,148			(738,163	)
Finance expenses		(7,441	)		(10,844	)		3,403
Foreign exchange result		(4,778,812	)		2,535,787			(7,314,599	)
Other financial result		6,963,097			103,285			6,859,812
Income taxes		—			—			—
Income (loss) for the period		(22,730,298	)		(23,502,977	)		772,678
Exchange differences on translation of foreign currency		(264,271	)		2,836			(267,107	)
Total comprehensive income (loss)		(22,994,569	)		(23,500,141	)		505,571

●	InflaRx working diligently toward unblinding of stopped Phase 3 pyoderma gangrenosum (PG) trial so that all data can be analyzed later this year

	June 30, 2025 (unaudited)			December 31, 2024
	(in €)
ASSETS
Non-current assets
Property and equipment		247,027			256,280
Right-of-use assets		559,286			758,368
Intangible assets		50,106			50,781
Other assets		177,716			204,233
Financial assets		6,235,346			3,092,290
Total non-current assets		7,269,480			4,361,952
Current assets
Inventories		5,038,415			6,897,666
Current other assets		5,519,954			5,103,402
Other assets from government grants and research allowance		5,863,947			5,081,772
Tax receivables		1,753,638			1,735,335
Financial assets		34,993,289			34,462,352
Cash and cash equivalents		13,003,450			18,375,979
Total current assets		66,172,692			71,656,505
TOTAL ASSETS		73,442,172			76,018,457

EQUITY AND LIABILITIES
Equity
Issued capital		8,129,656			7,122,205
Share premium		348,956,615			334,929,685
Other capital reserves		47,704,375			44,115,861
Accumulated deficit		(354,922,519	)		(332,192,221	)
Other components of equity		7,176,239			7,440,510
Total equity		57,044,365			61,416,039
Non-current liabilities
Lease liabilities		203,878			399,066
Other liabilities		36,877			36,877
Total non-current liabilities		240,755			435,943
Current liabilities
Trade and other payables		9,735,656			11,394,232
Lease liabilities		395,234			406,020
Employee benefits		1,114,635			2,064,678
Liabilities to warrant holders		4,549,915			—
Other liabilities		361,613			301,544
Total current liabilities		16,157,053			14,166,475
Total liabilities		16,397,808			14,602,417
TOTAL EQUITY AND LIABILITIES		73,442,172			76,018,457

	As of June 30, 2025 (unaudited)		As of December 31, 2024
	(in €)

Accrued liabilities from R&D projects		6,050,837		6,609,925
Accrued liabilities from commercial activities		109,000		69,250
Accounts payable		1,986,096		3,413,064
Other accrued liabilities and payables		1,951,336		1,603,538
Total		10,097,269		11,695,777

	As of June 30, 2025 (unaudited)		As of December 31, 2024
	(in €)
Short-term deposits
Deposits held in U.S. dollars		6,480,429		13,408,478
Deposits held in euros		2,590,000		700,000
Total		9,070,429		14,108,478
Cash at banks
Cash held in U.S. dollars		2,925,967		2,805,655
Cash held in euros		1,007,055		1,461,847
Total		3,933,022		4,267,501
Total cash and cash equivalents		13,003,450		18,375,979